A Phase 1b Study to Evaluate the Safety and PK of MP-376 in Chronic Obstructive Pulmonary Disease (COPD) Patients
| Status: | Completed |
|---|---|
| Conditions: | Chronic Obstructive Pulmonary Disease, Pulmonary |
| Therapuetic Areas: | Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 40 - Any |
| Updated: | 1/21/2018 |
| Start Date: | July 2008 |
| End Date: | October 2008 |
Phase 1b, Randomized, Single-Blind, Placebo-Controlled, Study to Evaluate the Safety, Tolerability and Pharmacokinetics of MP-376 Inhalation Solution Administered for 5 Days to Chronic Bronchitis Patients
Patients with Chronic Obstructive Pulmonary Disease (COPD) suffer from frequent and recurrent
acute exacerbations (AECB) which are associated with enormous healthcare expenditures and
significant morbidity, specifically an increased risk of death, a decline in pulmonary
function and a significant change in quality of life. Bacteria appear to have an important
role in acute exacerbations in chronic bronchitis and COPD. Studies of acute exacerbations in
COPD have shown a reduction in bacterial load with prolonged exacerbation-free interval. In
addition, recent studies indicate that acquisition of a new strain of H. influenzae, M.
catarrhalis, S. pneumoniae or P. aeruginosa are responsible for many of these exacerbations.
Chronic inflammation and bacterial infection predispose many patients to frequent and
recurrent acute exacerbations.
Mpex, (the sponsor on record at time of the study's initial registration) believes that
intermittent administration of inhaled MP-376 in high risk patients will decrease the
incidence of acute exacerbations by both by lowering the organism burden, and resultant
inflammation, as well as pre-emptive eradication of any newly acquired bacterial strains.
acute exacerbations (AECB) which are associated with enormous healthcare expenditures and
significant morbidity, specifically an increased risk of death, a decline in pulmonary
function and a significant change in quality of life. Bacteria appear to have an important
role in acute exacerbations in chronic bronchitis and COPD. Studies of acute exacerbations in
COPD have shown a reduction in bacterial load with prolonged exacerbation-free interval. In
addition, recent studies indicate that acquisition of a new strain of H. influenzae, M.
catarrhalis, S. pneumoniae or P. aeruginosa are responsible for many of these exacerbations.
Chronic inflammation and bacterial infection predispose many patients to frequent and
recurrent acute exacerbations.
Mpex, (the sponsor on record at time of the study's initial registration) believes that
intermittent administration of inhaled MP-376 in high risk patients will decrease the
incidence of acute exacerbations by both by lowering the organism burden, and resultant
inflammation, as well as pre-emptive eradication of any newly acquired bacterial strains.
This study will be a Phase 1b, multi-center, randomized, single-blind, placebo-controlled
study to evaluate the safety, tolerability, and pharmacokinetics of MP-376 solution for
inhalation given for 5 days to COPD patients.
study to evaluate the safety, tolerability, and pharmacokinetics of MP-376 solution for
inhalation given for 5 days to COPD patients.
Inclusion Criteria (selected):
- >/= 40 years of age
- History of COPD
- FEV1
- Clinically stable with no changes in health status within the last 30 days
- Lifetime smoking history of at least 15 pack-years
- Willing and able to give informed consent
Exclusion Criteria (selected):
- Use of any systemic or inhaled antibiotics within 30 days prior to baseline
- History of hypersensitivity to fluoroquinolones or intolerance with aerosol medication
- CrCl < 50/ml/min, AST, ALT or total bilirubin >/= 3 x ULN at Screening
- Significant or unstable medical conditions
We found this trial at
5
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials